Medical Devices & Consumables
Global Adeno-Associated Virus Vectors in Gene Therapy Market Research Report 2025
- Mar 14, 25
- ID: 133654
- Pages: 95
- Figures: 96
- Views: 18
The global market for Adeno-Associated Virus Vectors in Gene Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Adeno-associated viruses (AAV) are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae. They are small (20 nm) replication-defective, nonenveloped viruses and have linear single-stranded DNA (ssDNA) genome of approximately 4.8 kilobases (kb).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Adeno-Associated Virus Vectors in Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adeno-Associated Virus Vectors in Gene Therapy.
The Adeno-Associated Virus Vectors in Gene Therapy market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Adeno-Associated Virus Vectors in Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adeno-Associated Virus Vectors in Gene Therapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Amicus Therapeutics
Asklepios Biopharmaceutical
BioMarin Pharmaceutical
Coave Therapeutics
MeiraGTx
Neurocrine Biosciences
Pfizer
Roche Holding
Sangamo Therapeutics
Sarepta Therapeutics
Spark Therapeutics
Voyager Therapeutics
NightstaRx
Segment by Type
Serotype 2 (AVV 2)
Synthetic Serotypes
Others
Segment by Application
Alzheimer's Disease
Cystic Dibrosis
Hemophilia B
Parkinson's Disease
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Adeno-Associated Virus Vectors in Gene Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Adeno-Associated Virus Vectors in Gene Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Adeno-associated viruses (AAV) are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae. They are small (20 nm) replication-defective, nonenveloped viruses and have linear single-stranded DNA (ssDNA) genome of approximately 4.8 kilobases (kb).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Adeno-Associated Virus Vectors in Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adeno-Associated Virus Vectors in Gene Therapy.
The Adeno-Associated Virus Vectors in Gene Therapy market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Adeno-Associated Virus Vectors in Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adeno-Associated Virus Vectors in Gene Therapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Amicus Therapeutics
Asklepios Biopharmaceutical
BioMarin Pharmaceutical
Coave Therapeutics
MeiraGTx
Neurocrine Biosciences
Pfizer
Roche Holding
Sangamo Therapeutics
Sarepta Therapeutics
Spark Therapeutics
Voyager Therapeutics
NightstaRx
Segment by Type
Serotype 2 (AVV 2)
Synthetic Serotypes
Others
Segment by Application
Alzheimer's Disease
Cystic Dibrosis
Hemophilia B
Parkinson's Disease
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Adeno-Associated Virus Vectors in Gene Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Adeno-Associated Virus Vectors in Gene Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Adeno-Associated Virus Vectors in Gene Therapy Market Overview
1.1 Product Definition
1.2 Adeno-Associated Virus Vectors in Gene Therapy by Type
1.2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Market Value Comparison by Type (2024 VS 2031)
1.2.2 Serotype 2 (AVV 2)
1.2.3 Synthetic Serotypes
1.2.4 Others
1.3 Adeno-Associated Virus Vectors in Gene Therapy by Application
1.3.1 Global Adeno-Associated Virus Vectors in Gene Therapy Market Value by Application (2024 VS 2031)
1.3.2 Alzheimer's Disease
1.3.3 Cystic Dibrosis
1.3.4 Hemophilia B
1.3.5 Parkinson's Disease
1.4 Global Adeno-Associated Virus Vectors in Gene Therapy Market Size Estimates and Forecasts
1.4.1 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue 2020-2031
1.4.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales 2020-2031
1.4.3 Global Adeno-Associated Virus Vectors in Gene Therapy Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Adeno-Associated Virus Vectors in Gene Therapy Market Competition by Manufacturers
2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Manufacturers (2020-2025)
2.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Adeno-Associated Virus Vectors in Gene Therapy Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Adeno-Associated Virus Vectors in Gene Therapy, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Product Type & Application
2.7 Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Date of Enter into This Industry
2.8 Global Adeno-Associated Virus Vectors in Gene Therapy Market Competitive Situation and Trends
2.8.1 Global Adeno-Associated Virus Vectors in Gene Therapy Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Adeno-Associated Virus Vectors in Gene Therapy Players Market Share by Revenue
2.8.3 Global Adeno-Associated Virus Vectors in Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Adeno-Associated Virus Vectors in Gene Therapy Market Scenario by Region
3.1 Global Adeno-Associated Virus Vectors in Gene Therapy Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region: 2020-2031
3.2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region: 2020-2025
3.2.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region: 2026-2031
3.3 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region: 2020-2031
3.3.1 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region: 2020-2025
3.3.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region: 2026-2031
3.4 North America Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Country
3.4.1 North America Adeno-Associated Virus Vectors in Gene Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2031)
3.4.3 North America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Country
3.5.1 Europe Adeno-Associated Virus Vectors in Gene Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2031)
3.5.3 Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Region
3.6.1 Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2020-2031)
3.6.3 Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Country
3.7.1 Latin America Adeno-Associated Virus Vectors in Gene Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2031)
3.7.3 Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Country
3.8.1 Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2031)
3.8.3 Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Type (2020-2031)
4.1.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Type (2020-2025)
4.1.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Type (2026-2031)
4.1.3 Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Type (2020-2031)
4.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Type (2020-2031)
4.2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Type (2020-2025)
4.2.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Type (2026-2031)
4.2.3 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Type (2020-2031)
4.3 Global Adeno-Associated Virus Vectors in Gene Therapy Price by Type (2020-2031)
5 Segment by Application
5.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Application (2020-2031)
5.1.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Application (2020-2025)
5.1.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Application (2026-2031)
5.1.3 Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Application (2020-2031)
5.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Application (2020-2031)
5.2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Application (2020-2025)
5.2.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Application (2026-2031)
5.2.3 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Application (2020-2031)
5.3 Global Adeno-Associated Virus Vectors in Gene Therapy Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Amicus Therapeutics
6.1.1 Amicus Therapeutics Company Information
6.1.2 Amicus Therapeutics Description and Business Overview
6.1.3 Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.1.5 Amicus Therapeutics Recent Developments/Updates
6.2 Asklepios Biopharmaceutical
6.2.1 Asklepios Biopharmaceutical Company Information
6.2.2 Asklepios Biopharmaceutical Description and Business Overview
6.2.3 Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.2.5 Asklepios Biopharmaceutical Recent Developments/Updates
6.3 BioMarin Pharmaceutical
6.3.1 BioMarin Pharmaceutical Company Information
6.3.2 BioMarin Pharmaceutical Description and Business Overview
6.3.3 BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.3.4 BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.3.5 BioMarin Pharmaceutical Recent Developments/Updates
6.4 Coave Therapeutics
6.4.1 Coave Therapeutics Company Information
6.4.2 Coave Therapeutics Description and Business Overview
6.4.3 Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.4.5 Coave Therapeutics Recent Developments/Updates
6.5 MeiraGTx
6.5.1 MeiraGTx Company Information
6.5.2 MeiraGTx Description and Business Overview
6.5.3 MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.5.4 MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.5.5 MeiraGTx Recent Developments/Updates
6.6 Neurocrine Biosciences
6.6.1 Neurocrine Biosciences Company Information
6.6.2 Neurocrine Biosciences Description and Business Overview
6.6.3 Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.6.5 Neurocrine Biosciences Recent Developments/Updates
6.7 Pfizer
6.7.1 Pfizer Company Information
6.7.2 Pfizer Description and Business Overview
6.7.3 Pfizer Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Pfizer Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Roche Holding
6.8.1 Roche Holding Company Information
6.8.2 Roche Holding Description and Business Overview
6.8.3 Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.8.5 Roche Holding Recent Developments/Updates
6.9 Sangamo Therapeutics
6.9.1 Sangamo Therapeutics Company Information
6.9.2 Sangamo Therapeutics Description and Business Overview
6.9.3 Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.9.5 Sangamo Therapeutics Recent Developments/Updates
6.10 Sarepta Therapeutics
6.10.1 Sarepta Therapeutics Company Information
6.10.2 Sarepta Therapeutics Description and Business Overview
6.10.3 Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.10.5 Sarepta Therapeutics Recent Developments/Updates
6.11 Spark Therapeutics
6.11.1 Spark Therapeutics Company Information
6.11.2 Spark Therapeutics Description and Business Overview
6.11.3 Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.11.5 Spark Therapeutics Recent Developments/Updates
6.12 Voyager Therapeutics
6.12.1 Voyager Therapeutics Company Information
6.12.2 Voyager Therapeutics Description and Business Overview
6.12.3 Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.12.5 Voyager Therapeutics Recent Developments/Updates
6.13 NightstaRx
6.13.1 NightstaRx Company Information
6.13.2 NightstaRx Description and Business Overview
6.13.3 NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.13.4 NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.13.5 NightstaRx Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adeno-Associated Virus Vectors in Gene Therapy Industry Chain Analysis
7.2 Adeno-Associated Virus Vectors in Gene Therapy Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adeno-Associated Virus Vectors in Gene Therapy Production Mode & Process Analysis
7.4 Adeno-Associated Virus Vectors in Gene Therapy Sales and Marketing
7.4.1 Adeno-Associated Virus Vectors in Gene Therapy Sales Channels
7.4.2 Adeno-Associated Virus Vectors in Gene Therapy Distributors
7.5 Adeno-Associated Virus Vectors in Gene Therapy Customer Analysis
8 Adeno-Associated Virus Vectors in Gene Therapy Market Dynamics
8.1 Adeno-Associated Virus Vectors in Gene Therapy Industry Trends
8.2 Adeno-Associated Virus Vectors in Gene Therapy Market Drivers
8.3 Adeno-Associated Virus Vectors in Gene Therapy Market Challenges
8.4 Adeno-Associated Virus Vectors in Gene Therapy Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Adeno-Associated Virus Vectors in Gene Therapy by Type
1.2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Market Value Comparison by Type (2024 VS 2031)
1.2.2 Serotype 2 (AVV 2)
1.2.3 Synthetic Serotypes
1.2.4 Others
1.3 Adeno-Associated Virus Vectors in Gene Therapy by Application
1.3.1 Global Adeno-Associated Virus Vectors in Gene Therapy Market Value by Application (2024 VS 2031)
1.3.2 Alzheimer's Disease
1.3.3 Cystic Dibrosis
1.3.4 Hemophilia B
1.3.5 Parkinson's Disease
1.4 Global Adeno-Associated Virus Vectors in Gene Therapy Market Size Estimates and Forecasts
1.4.1 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue 2020-2031
1.4.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales 2020-2031
1.4.3 Global Adeno-Associated Virus Vectors in Gene Therapy Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Adeno-Associated Virus Vectors in Gene Therapy Market Competition by Manufacturers
2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Manufacturers (2020-2025)
2.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Adeno-Associated Virus Vectors in Gene Therapy Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Adeno-Associated Virus Vectors in Gene Therapy, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Product Type & Application
2.7 Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Date of Enter into This Industry
2.8 Global Adeno-Associated Virus Vectors in Gene Therapy Market Competitive Situation and Trends
2.8.1 Global Adeno-Associated Virus Vectors in Gene Therapy Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Adeno-Associated Virus Vectors in Gene Therapy Players Market Share by Revenue
2.8.3 Global Adeno-Associated Virus Vectors in Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Adeno-Associated Virus Vectors in Gene Therapy Market Scenario by Region
3.1 Global Adeno-Associated Virus Vectors in Gene Therapy Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region: 2020-2031
3.2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region: 2020-2025
3.2.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region: 2026-2031
3.3 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region: 2020-2031
3.3.1 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region: 2020-2025
3.3.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region: 2026-2031
3.4 North America Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Country
3.4.1 North America Adeno-Associated Virus Vectors in Gene Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2031)
3.4.3 North America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Country
3.5.1 Europe Adeno-Associated Virus Vectors in Gene Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2031)
3.5.3 Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Region
3.6.1 Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2020-2031)
3.6.3 Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Country
3.7.1 Latin America Adeno-Associated Virus Vectors in Gene Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2031)
3.7.3 Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Country
3.8.1 Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2031)
3.8.3 Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Type (2020-2031)
4.1.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Type (2020-2025)
4.1.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Type (2026-2031)
4.1.3 Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Type (2020-2031)
4.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Type (2020-2031)
4.2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Type (2020-2025)
4.2.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Type (2026-2031)
4.2.3 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Type (2020-2031)
4.3 Global Adeno-Associated Virus Vectors in Gene Therapy Price by Type (2020-2031)
5 Segment by Application
5.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Application (2020-2031)
5.1.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Application (2020-2025)
5.1.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Application (2026-2031)
5.1.3 Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Application (2020-2031)
5.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Application (2020-2031)
5.2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Application (2020-2025)
5.2.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Application (2026-2031)
5.2.3 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Application (2020-2031)
5.3 Global Adeno-Associated Virus Vectors in Gene Therapy Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Amicus Therapeutics
6.1.1 Amicus Therapeutics Company Information
6.1.2 Amicus Therapeutics Description and Business Overview
6.1.3 Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.1.5 Amicus Therapeutics Recent Developments/Updates
6.2 Asklepios Biopharmaceutical
6.2.1 Asklepios Biopharmaceutical Company Information
6.2.2 Asklepios Biopharmaceutical Description and Business Overview
6.2.3 Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.2.5 Asklepios Biopharmaceutical Recent Developments/Updates
6.3 BioMarin Pharmaceutical
6.3.1 BioMarin Pharmaceutical Company Information
6.3.2 BioMarin Pharmaceutical Description and Business Overview
6.3.3 BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.3.4 BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.3.5 BioMarin Pharmaceutical Recent Developments/Updates
6.4 Coave Therapeutics
6.4.1 Coave Therapeutics Company Information
6.4.2 Coave Therapeutics Description and Business Overview
6.4.3 Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.4.5 Coave Therapeutics Recent Developments/Updates
6.5 MeiraGTx
6.5.1 MeiraGTx Company Information
6.5.2 MeiraGTx Description and Business Overview
6.5.3 MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.5.4 MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.5.5 MeiraGTx Recent Developments/Updates
6.6 Neurocrine Biosciences
6.6.1 Neurocrine Biosciences Company Information
6.6.2 Neurocrine Biosciences Description and Business Overview
6.6.3 Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.6.5 Neurocrine Biosciences Recent Developments/Updates
6.7 Pfizer
6.7.1 Pfizer Company Information
6.7.2 Pfizer Description and Business Overview
6.7.3 Pfizer Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Pfizer Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Roche Holding
6.8.1 Roche Holding Company Information
6.8.2 Roche Holding Description and Business Overview
6.8.3 Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.8.5 Roche Holding Recent Developments/Updates
6.9 Sangamo Therapeutics
6.9.1 Sangamo Therapeutics Company Information
6.9.2 Sangamo Therapeutics Description and Business Overview
6.9.3 Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.9.5 Sangamo Therapeutics Recent Developments/Updates
6.10 Sarepta Therapeutics
6.10.1 Sarepta Therapeutics Company Information
6.10.2 Sarepta Therapeutics Description and Business Overview
6.10.3 Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.10.5 Sarepta Therapeutics Recent Developments/Updates
6.11 Spark Therapeutics
6.11.1 Spark Therapeutics Company Information
6.11.2 Spark Therapeutics Description and Business Overview
6.11.3 Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.11.5 Spark Therapeutics Recent Developments/Updates
6.12 Voyager Therapeutics
6.12.1 Voyager Therapeutics Company Information
6.12.2 Voyager Therapeutics Description and Business Overview
6.12.3 Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.12.5 Voyager Therapeutics Recent Developments/Updates
6.13 NightstaRx
6.13.1 NightstaRx Company Information
6.13.2 NightstaRx Description and Business Overview
6.13.3 NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2020-2025)
6.13.4 NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio
6.13.5 NightstaRx Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adeno-Associated Virus Vectors in Gene Therapy Industry Chain Analysis
7.2 Adeno-Associated Virus Vectors in Gene Therapy Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adeno-Associated Virus Vectors in Gene Therapy Production Mode & Process Analysis
7.4 Adeno-Associated Virus Vectors in Gene Therapy Sales and Marketing
7.4.1 Adeno-Associated Virus Vectors in Gene Therapy Sales Channels
7.4.2 Adeno-Associated Virus Vectors in Gene Therapy Distributors
7.5 Adeno-Associated Virus Vectors in Gene Therapy Customer Analysis
8 Adeno-Associated Virus Vectors in Gene Therapy Market Dynamics
8.1 Adeno-Associated Virus Vectors in Gene Therapy Industry Trends
8.2 Adeno-Associated Virus Vectors in Gene Therapy Market Drivers
8.3 Adeno-Associated Virus Vectors in Gene Therapy Market Challenges
8.4 Adeno-Associated Virus Vectors in Gene Therapy Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Adeno-Associated Virus Vectors in Gene Therapy Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Adeno-Associated Virus Vectors in Gene Therapy Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Adeno-Associated Virus Vectors in Gene Therapy Market Competitive Situation by Manufacturers in 2024
Table 4. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) of Key Manufacturers (2020-2025)
Table 5. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Adeno-Associated Virus Vectors in Gene Therapy Average Price (US$/Kg) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Adeno-Associated Virus Vectors in Gene Therapy, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Product Type & Application
Table 12. Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Adeno-Associated Virus Vectors in Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus Vectors in Gene Therapy as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Adeno-Associated Virus Vectors in Gene Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2020-2025) & (Kg)
Table 18. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Region (2020-2025)
Table 19. Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2026-2031) & (Kg)
Table 20. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Region (2026-2031)
Table 21. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Region (2020-2025)
Table 23. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Region (2026-2031)
Table 25. North America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2025) & (Kg)
Table 27. North America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2026-2031) & (Kg)
Table 28. North America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2025) & (Kg)
Table 32. Europe Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2026-2031) & (Kg)
Table 33. Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2020-2025) & (Kg)
Table 37. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2026-2031) & (Kg)
Table 38. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2025) & (Kg)
Table 42. Latin America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2026-2031) & (Kg)
Table 43. Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2025) & (Kg)
Table 47. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2026-2031) & (Kg)
Table 48. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) by Type (2020-2025)
Table 51. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) by Type (2026-2031)
Table 52. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Type (2020-2025)
Table 53. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Type (2026-2031)
Table 54. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Type (2020-2025)
Table 57. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Type (2026-2031)
Table 58. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Type (2020-2025)
Table 59. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Type (2026-2031)
Table 60. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) by Application (2020-2025)
Table 61. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) by Application (2026-2031)
Table 62. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Application (2020-2025)
Table 63. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Application (2026-2031)
Table 64. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Application (2020-2025)
Table 67. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Application (2026-2031)
Table 68. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Application (2020-2025)
Table 69. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Application (2026-2031)
Table 70. Amicus Therapeutics Company Information
Table 71. Amicus Therapeutics Description and Business Overview
Table 72. Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 73. Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product
Table 74. Amicus Therapeutics Recent Developments/Updates
Table 75. Asklepios Biopharmaceutical Company Information
Table 76. Asklepios Biopharmaceutical Description and Business Overview
Table 77. Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 78. Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Product
Table 79. Asklepios Biopharmaceutical Recent Developments/Updates
Table 80. BioMarin Pharmaceutical Company Information
Table 81. BioMarin Pharmaceutical Description and Business Overview
Table 82. BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 83. BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Product
Table 84. BioMarin Pharmaceutical Recent Developments/Updates
Table 85. Coave Therapeutics Company Information
Table 86. Coave Therapeutics Description and Business Overview
Table 87. Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 88. Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product
Table 89. Coave Therapeutics Recent Developments/Updates
Table 90. MeiraGTx Company Information
Table 91. MeiraGTx Description and Business Overview
Table 92. MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 93. MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Product
Table 94. MeiraGTx Recent Developments/Updates
Table 95. Neurocrine Biosciences Company Information
Table 96. Neurocrine Biosciences Description and Business Overview
Table 97. Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 98. Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Product
Table 99. Neurocrine Biosciences Recent Developments/Updates
Table 100. Pfizer Company Information
Table 101. Pfizer Description and Business Overview
Table 102. Pfizer Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 103. Pfizer Adeno-Associated Virus Vectors in Gene Therapy Product
Table 104. Pfizer Recent Developments/Updates
Table 105. Roche Holding Company Information
Table 106. Roche Holding Description and Business Overview
Table 107. Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 108. Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Product
Table 109. Roche Holding Recent Developments/Updates
Table 110. Sangamo Therapeutics Company Information
Table 111. Sangamo Therapeutics Description and Business Overview
Table 112. Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 113. Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product
Table 114. Sangamo Therapeutics Recent Developments/Updates
Table 115. Sarepta Therapeutics Company Information
Table 116. Sarepta Therapeutics Description and Business Overview
Table 117. Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 118. Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product
Table 119. Sarepta Therapeutics Recent Developments/Updates
Table 120. Spark Therapeutics Company Information
Table 121. Spark Therapeutics Description and Business Overview
Table 122. Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 123. Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product
Table 124. Spark Therapeutics Recent Developments/Updates
Table 125. Voyager Therapeutics Company Information
Table 126. Voyager Therapeutics Description and Business Overview
Table 127. Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 128. Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product
Table 129. Voyager Therapeutics Recent Developments/Updates
Table 130. NightstaRx Company Information
Table 131. NightstaRx Description and Business Overview
Table 132. NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 133. NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Product
Table 134. NightstaRx Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Adeno-Associated Virus Vectors in Gene Therapy Distributors List
Table 138. Adeno-Associated Virus Vectors in Gene Therapy Customers List
Table 139. Adeno-Associated Virus Vectors in Gene Therapy Market Trends
Table 140. Adeno-Associated Virus Vectors in Gene Therapy Market Drivers
Table 141. Adeno-Associated Virus Vectors in Gene Therapy Market Challenges
Table 142. Adeno-Associated Virus Vectors in Gene Therapy Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Adeno-Associated Virus Vectors in Gene Therapy
Figure 2. Global Adeno-Associated Virus Vectors in Gene Therapy Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Adeno-Associated Virus Vectors in Gene Therapy Market Share by Type: 2024 & 2031
Figure 4. Serotype 2 (AVV 2) Product Picture
Figure 5. Synthetic Serotypes Product Picture
Figure 6. Others Product Picture
Figure 7. Global Adeno-Associated Virus Vectors in Gene Therapy Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Adeno-Associated Virus Vectors in Gene Therapy Market Share by Application: 2024 & 2031
Figure 9. Alzheimer's Disease
Figure 10. Cystic Dibrosis
Figure 11. Hemophilia B
Figure 12. Parkinson's Disease
Figure 13. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Adeno-Associated Virus Vectors in Gene Therapy Market Size (2020-2031) & (US$ Million)
Figure 15. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (2020-2031) & (Kg)
Figure 16. Global Adeno-Associated Virus Vectors in Gene Therapy Average Price (US$/Kg) & (2020-2031)
Figure 17. Adeno-Associated Virus Vectors in Gene Therapy Report Years Considered
Figure 18. Adeno-Associated Virus Vectors in Gene Therapy Sales Share by Manufacturers in 2024
Figure 19. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Share by Manufacturers in 2024
Figure 20. Global 5 and 10 Largest Adeno-Associated Virus Vectors in Gene Therapy Players: Market Share by Revenue in Adeno-Associated Virus Vectors in Gene Therapy in 2024
Figure 21. Adeno-Associated Virus Vectors in Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Global Adeno-Associated Virus Vectors in Gene Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 23. North America Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Country (2020-2031)
Figure 24. North America Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Country (2020-2031)
Figure 25. United States Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Canada Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Europe Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Country (2020-2031)
Figure 28. Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Country (2020-2031)
Figure 29. Germany Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. France Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. U.K. Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Italy Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Russia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Region (2020-2031)
Figure 35. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Region (2020-2031)
Figure 36. China Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Japan Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. South Korea Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. India Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Australia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. China Taiwan Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Indonesia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Thailand Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Malaysia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Latin America Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Country (2020-2031)
Figure 46. Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Country (2020-2031)
Figure 47. Mexico Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Brazil Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Argentina Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Country (2020-2031)
Figure 52. Turkey Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. UAE Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Global Sales Market Share of Adeno-Associated Virus Vectors in Gene Therapy by Type (2020-2031)
Figure 56. Global Revenue Market Share of Adeno-Associated Virus Vectors in Gene Therapy by Type (2020-2031)
Figure 57. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Type (2020-2031)
Figure 58. Global Sales Market Share of Adeno-Associated Virus Vectors in Gene Therapy by Application (2020-2031)
Figure 59. Global Revenue Market Share of Adeno-Associated Virus Vectors in Gene Therapy by Application (2020-2031)
Figure 60. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Application (2020-2031)
Figure 61. Adeno-Associated Virus Vectors in Gene Therapy Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Table 1. Global Adeno-Associated Virus Vectors in Gene Therapy Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Adeno-Associated Virus Vectors in Gene Therapy Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Adeno-Associated Virus Vectors in Gene Therapy Market Competitive Situation by Manufacturers in 2024
Table 4. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) of Key Manufacturers (2020-2025)
Table 5. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Adeno-Associated Virus Vectors in Gene Therapy Average Price (US$/Kg) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Adeno-Associated Virus Vectors in Gene Therapy, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Product Type & Application
Table 12. Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Adeno-Associated Virus Vectors in Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus Vectors in Gene Therapy as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Adeno-Associated Virus Vectors in Gene Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2020-2025) & (Kg)
Table 18. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Region (2020-2025)
Table 19. Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2026-2031) & (Kg)
Table 20. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Region (2026-2031)
Table 21. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Region (2020-2025)
Table 23. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Region (2026-2031)
Table 25. North America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2025) & (Kg)
Table 27. North America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2026-2031) & (Kg)
Table 28. North America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2025) & (Kg)
Table 32. Europe Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2026-2031) & (Kg)
Table 33. Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2020-2025) & (Kg)
Table 37. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2026-2031) & (Kg)
Table 38. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2025) & (Kg)
Table 42. Latin America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2026-2031) & (Kg)
Table 43. Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2020-2025) & (Kg)
Table 47. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2026-2031) & (Kg)
Table 48. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) by Type (2020-2025)
Table 51. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) by Type (2026-2031)
Table 52. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Type (2020-2025)
Table 53. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Type (2026-2031)
Table 54. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Type (2020-2025)
Table 57. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Type (2026-2031)
Table 58. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Type (2020-2025)
Table 59. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Type (2026-2031)
Table 60. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) by Application (2020-2025)
Table 61. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) by Application (2026-2031)
Table 62. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Application (2020-2025)
Table 63. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Application (2026-2031)
Table 64. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Application (2020-2025)
Table 67. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Application (2026-2031)
Table 68. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Application (2020-2025)
Table 69. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Application (2026-2031)
Table 70. Amicus Therapeutics Company Information
Table 71. Amicus Therapeutics Description and Business Overview
Table 72. Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 73. Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product
Table 74. Amicus Therapeutics Recent Developments/Updates
Table 75. Asklepios Biopharmaceutical Company Information
Table 76. Asklepios Biopharmaceutical Description and Business Overview
Table 77. Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 78. Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Product
Table 79. Asklepios Biopharmaceutical Recent Developments/Updates
Table 80. BioMarin Pharmaceutical Company Information
Table 81. BioMarin Pharmaceutical Description and Business Overview
Table 82. BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 83. BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Product
Table 84. BioMarin Pharmaceutical Recent Developments/Updates
Table 85. Coave Therapeutics Company Information
Table 86. Coave Therapeutics Description and Business Overview
Table 87. Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 88. Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product
Table 89. Coave Therapeutics Recent Developments/Updates
Table 90. MeiraGTx Company Information
Table 91. MeiraGTx Description and Business Overview
Table 92. MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 93. MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Product
Table 94. MeiraGTx Recent Developments/Updates
Table 95. Neurocrine Biosciences Company Information
Table 96. Neurocrine Biosciences Description and Business Overview
Table 97. Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 98. Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Product
Table 99. Neurocrine Biosciences Recent Developments/Updates
Table 100. Pfizer Company Information
Table 101. Pfizer Description and Business Overview
Table 102. Pfizer Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 103. Pfizer Adeno-Associated Virus Vectors in Gene Therapy Product
Table 104. Pfizer Recent Developments/Updates
Table 105. Roche Holding Company Information
Table 106. Roche Holding Description and Business Overview
Table 107. Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 108. Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Product
Table 109. Roche Holding Recent Developments/Updates
Table 110. Sangamo Therapeutics Company Information
Table 111. Sangamo Therapeutics Description and Business Overview
Table 112. Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 113. Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product
Table 114. Sangamo Therapeutics Recent Developments/Updates
Table 115. Sarepta Therapeutics Company Information
Table 116. Sarepta Therapeutics Description and Business Overview
Table 117. Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 118. Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product
Table 119. Sarepta Therapeutics Recent Developments/Updates
Table 120. Spark Therapeutics Company Information
Table 121. Spark Therapeutics Description and Business Overview
Table 122. Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 123. Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product
Table 124. Spark Therapeutics Recent Developments/Updates
Table 125. Voyager Therapeutics Company Information
Table 126. Voyager Therapeutics Description and Business Overview
Table 127. Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 128. Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product
Table 129. Voyager Therapeutics Recent Developments/Updates
Table 130. NightstaRx Company Information
Table 131. NightstaRx Description and Business Overview
Table 132. NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 133. NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Product
Table 134. NightstaRx Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Adeno-Associated Virus Vectors in Gene Therapy Distributors List
Table 138. Adeno-Associated Virus Vectors in Gene Therapy Customers List
Table 139. Adeno-Associated Virus Vectors in Gene Therapy Market Trends
Table 140. Adeno-Associated Virus Vectors in Gene Therapy Market Drivers
Table 141. Adeno-Associated Virus Vectors in Gene Therapy Market Challenges
Table 142. Adeno-Associated Virus Vectors in Gene Therapy Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Adeno-Associated Virus Vectors in Gene Therapy
Figure 2. Global Adeno-Associated Virus Vectors in Gene Therapy Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Adeno-Associated Virus Vectors in Gene Therapy Market Share by Type: 2024 & 2031
Figure 4. Serotype 2 (AVV 2) Product Picture
Figure 5. Synthetic Serotypes Product Picture
Figure 6. Others Product Picture
Figure 7. Global Adeno-Associated Virus Vectors in Gene Therapy Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Adeno-Associated Virus Vectors in Gene Therapy Market Share by Application: 2024 & 2031
Figure 9. Alzheimer's Disease
Figure 10. Cystic Dibrosis
Figure 11. Hemophilia B
Figure 12. Parkinson's Disease
Figure 13. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Adeno-Associated Virus Vectors in Gene Therapy Market Size (2020-2031) & (US$ Million)
Figure 15. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (2020-2031) & (Kg)
Figure 16. Global Adeno-Associated Virus Vectors in Gene Therapy Average Price (US$/Kg) & (2020-2031)
Figure 17. Adeno-Associated Virus Vectors in Gene Therapy Report Years Considered
Figure 18. Adeno-Associated Virus Vectors in Gene Therapy Sales Share by Manufacturers in 2024
Figure 19. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Share by Manufacturers in 2024
Figure 20. Global 5 and 10 Largest Adeno-Associated Virus Vectors in Gene Therapy Players: Market Share by Revenue in Adeno-Associated Virus Vectors in Gene Therapy in 2024
Figure 21. Adeno-Associated Virus Vectors in Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Global Adeno-Associated Virus Vectors in Gene Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 23. North America Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Country (2020-2031)
Figure 24. North America Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Country (2020-2031)
Figure 25. United States Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Canada Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Europe Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Country (2020-2031)
Figure 28. Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Country (2020-2031)
Figure 29. Germany Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. France Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. U.K. Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Italy Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Russia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Region (2020-2031)
Figure 35. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Region (2020-2031)
Figure 36. China Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Japan Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. South Korea Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. India Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Australia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. China Taiwan Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Indonesia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Thailand Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Malaysia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Latin America Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Country (2020-2031)
Figure 46. Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Country (2020-2031)
Figure 47. Mexico Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Brazil Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Argentina Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Country (2020-2031)
Figure 52. Turkey Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. UAE Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Global Sales Market Share of Adeno-Associated Virus Vectors in Gene Therapy by Type (2020-2031)
Figure 56. Global Revenue Market Share of Adeno-Associated Virus Vectors in Gene Therapy by Type (2020-2031)
Figure 57. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Type (2020-2031)
Figure 58. Global Sales Market Share of Adeno-Associated Virus Vectors in Gene Therapy by Application (2020-2031)
Figure 59. Global Revenue Market Share of Adeno-Associated Virus Vectors in Gene Therapy by Application (2020-2031)
Figure 60. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Application (2020-2031)
Figure 61. Adeno-Associated Virus Vectors in Gene Therapy Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Gadolinium DOTA Meglumine Market Research Report 2025
Apr 23, 25
Global Crisaborole API Market Research Report 2025
Apr 23, 25
Global Glyceryl Monooleate Market Research Report 2025
Apr 23, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232